Textbook of clinical trials: Difference between revisions

Jump to navigation Jump to search
No edit summary
(Undo revision 1585825 by Skazmi (talk))
Tag: Undo
Line 35: Line 35:
[[Phase III trials|Phase 3 trials]]
[[Phase III trials|Phase 3 trials]]


[[Parallel study|Parallel]] versus [[Dose escalation study
[[Parallel study|Parallel]] versus dose escalation studies
|dose escalation studies]]


[[Hypothesis|Hypothesis generation]]
[[Hypothesis|Hypothesis generation]]
Line 46: Line 45:
[[Primary end point|Primary endpoint]]
[[Primary end point|Primary endpoint]]


[[Secondary end point|Secondary endpoints]] and [[Exploratory research|exploratory endpoints]]
Secondary endpoints and [[Exploratory research|exploratory endpoints]]


[[Surrogate endpoint|Surrogate endpoints]]
[[Surrogate endpoint|Surrogate endpoints]]

Revision as of 14:31, 25 October 2019


Designing Clinical Trials

Randomized controlled trials versus observational studies

Phase 1 trials

Pharmacokinetic (PK) and pharmcodynamic (PD) assessment

Phase 2 trials

Advancing from phase 2 to a phase 3 trial

Phase 3 trials

Parallel versus dose escalation studies

Hypothesis generation

Inclusion and exclusion criteria

Stratification

Primary endpoint

Secondary endpoints and exploratory endpoints

Surrogate endpoints

Sample size and power calculations

Protocol creation

Abbreviations used in clinical trials

Operationalizing Clinical Trials

Principal investigator role

Executive committee role

Steering committee role

Nurse coordinator clinical research associate role

Monitor role

Sponsor role

Randomization service

Central laboratory facility

EKG core laboratory

Angiographic core laboratory

MRI core laboratory

Genetics core laboratory

Biomarker core laboratory

Identification of sites

Randomization

Blinding

Recruitment of study participants

Electronic data collection

Schedule of events

Concomitant medications

Clinical event committee or event adjudication committee

(CEC)

Adverse events, serious adverse events and serious unexpected events

Data safety monitoring board (DSMB)

Study drug discontinuation, withdrawal of consent, incomplete follow up and lost to follow up patients

Protocol adherence

Storage and handling of the investigational product

Data management and designing an electronic data capture form

Source documents

Study completion and close out

Protocol amendments

Publication committee

Statistical Analysis of Clinical Trials

Cleaning a dataset

Summary statistics

Intent to treat versus modified intent to treat versus as treated

Student's t tests and analysis of variance (ANOVA)

Chi square analysis and Fisher's exact test

Logistic regression

Multivariate modeling

Survival analysis

Handling missing data

Subgroup and interaction analyses

Net clinical benefit analyses

Cost effectiveness analyses

Quality adjusted life year analyses

Interim analyses and futility analyses

Reporting results

How to write a manuscript

Meta-analysis

Positive publication bias


Study Tools

GFR calculation

TIMI Risk Score

Grace Risk Score